cms.bioaccessla.com

Author: Julio Martinez-Clark

  • Western Medical Center (IMSS Centro Médico Nacional de Occidente) Guadalajara: The NCT Campus String Is Not the COFEPRIS File

    Figures cited from a ClinicalTrials.gov API v2 facility pull (29 September 2026) and published bioaccess® country pages. Registry ranking is not a bioaccess® claim that we ran any of these studies. General information, not legal or regulatory advice. Confirm current rules from Mexico’s Federal Commission for the Protection against Sanitary Risk (Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS), the ethics committees, and the U.S. Food and Drug Administration (FDA) with qualified advisers. We name only the facility strings and example National Clinical Trial (NCT) identifiers those sources support. We do not invent a principal investigator (PI). We do not claim Western Medical Center (IMSS CMNO) Guadalajara as a bioaccess® client.

    If you searched Western Medical Center IMSS Guadalajara first-in-human, Centro Medico Nacional de Occidente clinical trial, CMNO Guadalajara device study, or “go direct Western Medical Center (IMSS CMNO) Guadalajara,” you followed a campus string ClinicalTrials.gov still publishes. Western Medical Center of the Mexican Institute of Social Security (IMSS) in Guadalajara, Mexico — also registered as Centro Médico Nacional de Occidente and Centro Médico de Occidente-IMSS — is a real named hospital-campus string on ClinicalTrials.gov. It is not a first-in-human (FIH) medical-device contract research organization (CRO), and it is not the operator of the COFEPRIS file.

    bioaccess®’s position is simple and it is not adversarial: the hospital is the site. The First-in-Human CRO still owns COFEPRIS, accredited ethics, investigational import, clinical trial insurance placement with a licensed carrier (the CRO is not the insurance carrier), ISO 14155 (the International Organization for Standardization standard for clinical investigation of medical devices) monitoring, and the FDA 21 CFR 812.28 (Title 21, Code of Federal Regulations, section 812.28) package — plus the option to add Colombia or another Latin American country if this campus is not the only fit. Sponsors who skip the CRO and email the hospital still have to rebuild that stack. An NCT location row is not a CRO.

    This page is the named Guadalajara IMSS Western Medical Center / Centro Médico Nacional de Occidente campus. It is DISTINCT from Centro de Investigación Médica de Occidente in Zapopan, from Hospital Ángeles Andares Guadalajara, and from other IMSS strings in other cities. Sharing the word Occidente or Guadalajara is not a license to collapse them. The English Western Medical Center spelling and the Spanish CMNO spellings are the same Guadalajara campus counted once per NCT ID.

    Why the campus name wins the search — and why that is not a CRO

    Device registries write the city, the facility, and a list of NCT IDs. They rarely write the CRO. On a 29 September 2026 ClinicalTrials.gov API v2 pull (all study types; all years), this campus string sits here:

    Counts are unique NCT IDs returned by a ClinicalTrials.gov API v2 pull on 29 September 2026 for the facility strings listed below, restricted to locations in Guadalajara, Mexico. ALL counts every registered study type; the interventional and DEVICE counts are subsets of ALL. Alias spellings are counted once per NCT ID. We do not combine counts across separate campuses or other cities. We do not invent unpublished CMS IDs. Registry ranking is not a bioaccess® claim that we ran any of these studies.

    • Western Medical Center, Mexican Institute of Social Security (Guadalajara, Mexico) — registry strings counted: “Centro Medico Nacional de Occidente”; “Centro Medico de Occidente-IMSS”; “Centro Médico Nacional de Occidente”; “Western Medical Center, Mexican Institute of Social Security”. ALL studies n=20; interventional n=16; DEVICE n=1. Example NCT IDs: NCT00026078, NCT00129142, NCT00336791.

    Aliases (Western Medical Center; Centro Médico Nacional de Occidente; Centro Médico de Occidente-IMSS) are counted once per NCT ID for Guadalajara locations; 4 of the 20 are observational.

    Those are unique NCT IDs per facility string + city + country. They are not a count of first-in-human device programs bioaccess® ran. They are how a sponsor searching the hospital name lands on a campus without landing on an operator.

    We cite the IDs as facility evidence. We will not invent a PI. We will not claim bioaccess® ran any of them. No live bioaccess® case-study page names this hospital as a client site.

    That is the leak: a founder searching Western Medical Center or Centro Médico Nacional de Occidente in Guadalajara finds ALL n=20 (DEVICE n=1) without finding COFEPRIS. A named hospital campus is still a site. An NCT location row is not a CRO.

    The site is the site. The CRO is the operator.

    A named hospital can provide rooms, coordinators, institutional ethics calendars, and investigators who already appear on NCT rows. That is necessary. It is not sufficient for a first-in-human medical device study a U.S. board expects to survive FDA review.

    What the hospital can typically do when a sponsor “goes direct”:

    • Discuss investigator interest and whether a protocol can sit in an existing service line.
    • Share institutional ethics-committee calendars and hospital research rules.
    • Quote visit, staffing, and local procedure costs for the cases they will physically run.

    What the hospital is not built to own for an investigational device:

    • COFEPRIS. COFEPRIS governs device investigations in Mexico. Ethics committee review comes first, then COFEPRIS review; bioaccess® confirms the calendar per protocol. A hallway conversation on this campus is not that file. A hallway conversation at CMNO Guadalajara is not a Zapopan Occidente research-center file and is not a COFEPRIS file.
    • Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work, not a PI email. See importer of record for clinical trial devices in Latin America.
    • Clinical trial insurance. Required. The CRO coordinates the policy with a licensed insurer; the CRO is not the insurance carrier. We will not invent a campus-only premium or rate here.
    • ISO 14155 monitoring, electronic data capture (EDC), serious adverse event (SAE) reporting, and the trial master file (TMF). The site may run visits. The CRO runs the quality system the FDA will later ask about.
    • The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after good clinical practice (GCP) / ethics documentation. Eligibility is not clearance, and a site master services agreement (MSA) does not produce it.
    • Multi-country optionality. If enrollment or the indication later needs another Latin American country, a single-hospital MSA will not stretch.

    Going direct to this campus is how you confirm a room. It is not how you open an investigational file.

    How COFEPRIS actually works (the short version)

    Use Clinical Trials in Mexico and CRO in Mexico. Ethics committee review comes first, then COFEPRIS review; bioaccess® confirms the calendar per protocol. Keep trial clocks separate from registro sanitario (~30 working days on that hub). Eligibility of foreign data under 21 CFR 812.28 is not a guarantee of clearance.

    Ask for a protocol-specific calendar. A hospital email is not COFEPRIS clearance. bioaccess® manages the file. That is CRO work, not site work.

    All bioaccess® device protocols in this country are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. See outside-the-United-States (OUS) FIH data and the FDA Investigational Device Exemption (IDE).

    Not a critique of the hospital

    Western Medical Center / Centro Médico Nacional de Occidente is a serious named Guadalajara IMSS campus on the public registry. ALL n=20 and DEVICE n=1 are registry volume, not a punchline. Use the site when the protocol fits. Hire the operator.

    What the CRO still does after you have the campus on a slide

    1. Regulatory-fit, not tourism. This geography is sourced. One campus is not automatically the right room for every indication. bioaccess® still runs trials in Colombia and the rest of the platform.
    2. Protocol, investigator’s brochure (IB), informed consent form (ICF), insurance, and the COFEPRIS / ethics packet.
    3. Importer of record and device accountability.
    4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate this campus only if it fits the protocol.
    5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Submission (Pre-Sub), IDE, 510(k) premarket notification, De Novo request, premarket approval (PMA), or humanitarian device exemption (HDE) — eligibility, not a promise of FDA action.

    The firm was founded in 2010. That is the operator layer around a campus string.

    Colombia is still on the map

    Public line: bioaccess® runs first-in-human studies in Colombia now — local entity, Miami headquarters, own CRO in Colombia. Colombia’s regulatory framework is changing for the better. INVIMA commercial registration remains. Ethics review in both Panama and Colombia runs on each committee’s meeting schedule. The country page’s published per-patient comparison: $12K–$22K vs. $15K–$25K as published on Clinical Trials in Panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

    Frequently asked questions

    Can I contract Western Medical Center (IMSS CMNO) Guadalajara directly for a device FIH?

    You can try. The hospital can discuss investigator interest, local visit costs, and ethics calendars. It cannot, by ranking on ClinicalTrials.gov, become your COFEPRIS applicant, importer of record, insurance coordinator, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the site if the site fits.

    Did bioaccess® run the NCT IDs listed here?

    No public bioaccess® case-study page names this hospital. We will not invent that claim. This page answers the search; it does not claim the studies.

    Is this the same page as Centro de Investigación Médica de Occidente Zapopan?

    No. Centro de Investigación Médica de Occidente Zapopan is a distinct Zapopan page already published. This page is the Guadalajara IMSS Western Medical Center / CMNO campus only.

    Did bioaccess® run NCT00026078?

    No. We cite it as facility evidence. We will not invent a sponsor or a PI.

    Next step

    If the search that brought you here was this campus, start as the operator: contact bioaccess® or book from First-in-Human CRO. Occidente sibling (do not merge): Centro de Investigación Médica de Occidente Zapopan.

    Julio G. Martinez-Clark, CEO · bioaccess®

  • LATAM rapid-startup archetypes: Chile, Costa Rica, Panama, and El Salvador selection matrix

    Four countries. Two archetypes. One decision: which startup design matches the evidence your board, QA, and first-patient-in date actually need.

    I am Julio Martinez-Clark, CEO of bioaccess®. This is Part 3 of the Latin America rapid-startup archetypes series — the comparative framework for Chile, Costa Rica, Panama, and El Salvador. Part 1: pure ethics committee approval. Part 2: parallel review models. Corridor overview: fast-track FIH corridor. Indicative clocks only — confirm on filing day. Not legal advice.

    The two archetypes side by side

    Dimension Pure ethics (Chile & Costa Rica) Parallel review (Panama & El Salvador)
    What authorizes trial start Accredited CEC / IRB decision Ethics + national authority, concurrent
    Ministry / regulator role on the protocol No sequential ministry protocol-science queue; import / registry logistics follow ethics MINSA (Panama) or SRS (El Salvador) evaluate alongside ethics
    Primary instruments Chile: Ley 20.120, Decreto 114. Costa Rica: Ley 9234 / CONIS-accredited CEC Panama: Decreto Ejecutivo 21/2026 Art. 91, Type II CBI, RESEGIS. El Salvador: SRS-CNEIS-ES
    Statutory / typical ethics clock Chile CEC: 45 calendar days (extendable once by 20 for founded reasons). Costa Rica: CONIS-accredited CEC + CONIS registration Panama: parallel ethics + MINSA; ~30–45 day startup when complete. El Salvador: CNEIS pleno timed to its meeting schedule; overall ~30–60 days
    Submission logistics Ethics package first; then ISP import (Chile) or CONIS registry (Costa Rica) One concurrent package into dual desks (RESEGIS/CBI or SRS-CNEIS-ES)
    Best when you need Clean ethics authorization without buying a ministry science co-signature Authority validation without sequential backlog

    Country cards for Clinical Ops, CMOs, and RA Directors

    Chile

    • Archetype: Pure ethics.
    • Clock to watch: Accredited CEC under Decreto 114 — 45 calendar days from complete submission.
    • Ministerial involvement: Not an ANAMED-style pharma IND sequential review for devices. ISP issues investigational-device import / provisional research-use authorization based on CEC clearance.
    • Operational lead time to FPI: Ethics calendar + ISP import readiness + site director authorization. Plan weeks after a clean CEC letter, not months of ministry protocol science.
    • Select Chile when: You want a statutory ethics clock, strong data-rigor perception, and a device path that does not wait on centralized pharma IND machinery.

    Costa Rica

    • Archetype: Pure ethics.
    • Clock to watch: Written approval from a CONIS-accredited CEC, then CONIS registration before execution.
    • Ministerial involvement: CONIS sits under the Ministry of Health structure for accreditation and registry. MINSA does not run a sequential protocol scientific review after ethics as the critical path.
    • Operational lead time to FPI: CEC decision + CONIS registration + site institutional authorization. Combined ethics-plus-registry work commonly lands in a weeks-to-low-months band when the Spanish file is complete — ask for a study-specific calendar.
    • Select Costa Rica when: You want Central American infrastructure, English-friendly operations, and an ethics-led start without inventing a ministry co-review that the archetype does not sell.

    Panama

    • Archetype: Parallel review.
    • Clock to watch: Decreto Ejecutivo 21/2026 Art. 91 — MINSA and CNBI-accredited Type II CBI evaluate simultaneously via RESEGIS mechanics. Complete-file startup often ~30–45 days.
    • Ministerial involvement: Explicit and concurrent. Registration on RESEGIS is mandatory before execution.
    • Operational lead time to FPI: Parallel clearance + import / DNFD touches where required + site activation. The sprinter reputation is real when the dossier is Spanish-complete on day one.
    • Select Panama when: You need ministry evaluation on the protocol and still need a weeks-scale startup. Use Type II, not Type I.

    El Salvador

    • Archetype: Parallel review.
    • Clock to watch: Unified SRS-CNEIS-ES submission; CNEIS pleno timed to its meeting schedule; overall clearance typically 30–60 days.
    • Ministerial / authority involvement: SRS and CNEIS review concurrently from one digital file.
    • Operational lead time to FPI: Platform clearance + hospital contracting + import readiness. Cost position is often favorable versus Panama; population depth still constrains recruitment modeling.
    • Select El Salvador when: You want one ethics body, one regulator, one submission — authority validation without sequential delay.

    Selection matrix — five filters before you pick

    1. Do you need a national regulator’s protocol evaluation on the docket?
      Yes → Panama or El Salvador. No → Chile or Costa Rica.
    2. Is your pain sequential backlog or ethics capacity?
      Sequential backlog → parallel archetype. Ethics calendar / Spanish file quality → fix the dossier before you change countries.
    3. Device vs drug path?
      Chile’s device story (outside ANAMED pharma IND; ISP import after CEC) is a specific MedTech advantage. Confirm drug paths separately — do not copy-paste the device matrix onto every IND.
    4. Recruitment honesty
      All four corridor countries are smaller than Brazil, Mexico, or Colombia. Fast startup is worthless if screening math is fiction. Model prevalence before you celebrate a 45-day ethics clock.
    5. Import and site reality
      FPI is ethics/regulator clearance plus device or drug on site plus contracts signed. Parallel review does not ship inventory. Pure ethics does not either.

    Indicative lead times to first-patient-in

    For the phases before submission (protocol, site selection, translation, insurance and contracts) and how they add up, see our phase-by-phase site activation timeline guide.

    Use these as planning bands for early-phase programs with a complete Spanish dossier, not as guarantees:

    • Chile: CEC 45-calendar-day frame + ISP import + site authorization → often a weeks-scale path after complete ethics submission.
    • Costa Rica: CONIS-accredited CEC + CONIS registration + site authorization → weeks to low months depending on committee cadence and file quality.
    • Panama: Parallel Type II + MINSA via RESEGIS → ~30–45 days to clearance on a complete file; FPI follows import and site readiness.
    • El Salvador: SRS-CNEIS-ES concurrent review → typically 30–60 days to clearance; CNEIS pleno timing inside that band follows its meeting schedule.

    If someone sells you “15 days to FPI” without naming dossier completeness, import status, and site contracts, they are selling a press line, not an operating plan. bioaccess® has activated fast Panama files; we still separate clearance clocks from first-patient clocks.

    How this series maps to the corridor post

    The corridor article answers “why these four countries feel fast.” This series answers “which legal design are you buying.” Speed without archetype clarity produces the wrong country for the wrong diligence question. Put both documents in the same diligence binder.

    Worked examples (no client names)

    Example A — implantable early feasibility, US IDE still months out. Board wants first-in-human data and does not require a ministry co-signature on the protocol science. Chile’s CEC clock under Decreto 114 plus ISP import after CEC is the cleaner fit than forcing a parallel-review country for optics.

    Example B — injectable or higher-visibility program where RA wants regulator eyes on the protocol. Panama Art. 91 parallel evaluation or El Salvador SRS-CNEIS-ES concurrent review answers the diligence question without a 6–12 month sequential stack.

    Example C — multi-country early program. Use Costa Rica or Chile for an ethics-led first site while a Panama or El Salvador file runs in parallel for authority-validated evidence. That is portfolio design. It is not “pick the fastest logo.”

    Diligence questions to send your CRO

    1. Which archetype are you selling me, in one sentence, with the named statute or platform?
    2. What starts the clock — complete-file date or first email?
    3. What is explicitly not included in the clearance clock (import, contracts, pharmacy)?
    4. For Panama: Type II CBI name and RESEGIS registration owner?
    5. For El Salvador: who holds the SRS-CNEIS-ES account and who answers queries inside the platform?
    6. For Chile: which accredited CEC and what is the ISP import dependency after the CEC letter?
    7. For Costa Rica: which CONIS-accredited CEC and when does CONIS registration occur relative to site activation?

    If the answers smear archetypes together, restart the country conversation before you restart the translation budget.

    Operator recommendation

    • MedTech FIH founder avoiding US IDE queue, wants ethics-led start: start with Chile or Costa Rica (Part 1).
    • Sponsor whose QA/RA needs concurrent authority evaluation: start with Panama or El Salvador (Part 2).
    • Portfolio with mixed programs: do not force one archetype. Match each protocol to the filter list above.

    bioaccess® — the First-in-Human CRO for medical devices in Latin America since 2010 — builds the dossier to the archetype you chose, not the one that sounds faster in a slide. Global Trial Accelerators™ and the country hubs on bioaccessla.com exist so your team can verify clocks against named instruments: Ley 20.120, Decreto 114, Ley 9234 / CONIS, Decreto Ejecutivo 21/2026 Art. 91, SRS-CNEIS-ES.

    Talk with bioaccess® when you need the four-country matrix turned into a study-specific startup calendar with Spanish file ownership, import sequencing, and an honest FPI date.

  • Parallel review in Panama and El Salvador: cutting sequential clinical trial backlogs

    Sequential startup is the silent killer of early-phase calendars. Ethics finishes. Then the ministry opens the protocol. Then someone asks for a Spanish annex you already had. Six to twelve months disappear before first-patient-in.

    I am Julio Martinez-Clark, CEO of bioaccess®. Panama and El Salvador sit in the second rapid-startup archetype: parallel review. Centralized authorities evaluate protocols at the same time as ethics committees. You still clear both gates. You stop waiting for them in series.

    This is Part 2 of the Latin America rapid-startup archetypes series. Part 1 covered pure ethics committee approval in Chile and Costa Rica. Part 3 is the comparative selection matrix. Corridor context: fast-track FIH corridor. Not legal advice — confirm the pathway on filing day.

    The archetype in one sentence

    Parallel review means the regulator and the ethics body work the same protocol package concurrently, so the traditional 6–12 month sequential backlog never becomes your critical path.

    Sponsors who need a national authority’s validation on the docket — without paying for that validation in serial months — belong here.

    Panama: Decreto Ejecutivo 21/2026, Art. 91, Type II CBIs, RESEGIS

    On 23 April 2026 Panama published Decreto Ejecutivo No. 21 (Gaceta Oficial No. 30510-C), implementing Titles III and IV of Ley 84 of 14 May 2019. For startup design, three pieces matter more than the rest of the decree:

    • RESEGIS — MINSA’s web platform for registro y seguimiento of health-research projects. Studies register before execution; the public docket is real, not folklore.
    • CNBI-accredited Type II CBIs — clinical trials go to Type II Comités de Bioética de la Investigación accredited by the national committee (CNBI). Ordinary ethics clocks are defined in the decree (including a 20-business-day ordinary review frame for complete files).
    • Artículo 91 parallel evaluation — for the high-risk / clinical-trial line, MINSA’s evaluation and the accredited Type II CBI review run simultaneously. The ministry review does not freeze the ethics clock.

    Operationally, that is why Panama startup compresses into roughly 30–45 days when the Spanish file is complete and the Type II committee is correctly selected. Parallelism is the design. Incomplete dossiers are still the failure mode.

    Operator checklist for Panama:

    1. Confirm the ethics destination is a CNBI-accredited Type II CBI. Type I is the wrong lane for interventional trials.
    2. Register the project in RESEGIS on the decree’s timeline — do not treat ethics approval as a substitute for registration.
    3. Submit a Spanish package that both MINSA and the CBI can review without translation theater: protocol, IB, consent, insurance, investigator and site docs.
    4. Plan import / pharmacy (including DNFD touchpoints where the product path requires them) as logistics that ride the RESEGIS + ethics + authorization chain — not as a surprise third sequential science review.
    5. Read the public RESEGIS list if you want proof the country is not opaque. The docket is an Excel-shaped reality, not a black box.

    Deeper Panama notes already published on the site: Decreto 21 of 2026 explained, CNBI / Type II procedure checklist, RESEGIS public trial docket, and functional animal studies vs Decreto 21.

    El Salvador: SRS-CNEIS-ES unified digital submission

    El Salvador’s parallel model is digital by design. Sponsors submit through the SRS-CNEIS-ES platform. One structured submission feeds both:

    • SRS — Superintendencia de Regulación Sanitaria (the national sanitary regulator; successor posture to the former DNM for this work), and
    • CNEIS — Comité Nacional de Ética de la Investigación en Salud.

    SRS and CNEIS review concurrently. You are not waiting for ethics to finish before the regulator opens the file, or the reverse. CNEIS pleno review runs on the committee’s own meeting schedule; overall clearance for a complete international protocol typically lands in 30–60 days.

    That combination — one ethics body with national authority for international pharmaceutical / clinical protocols, one regulator, one digital submission — is why sponsors who want authority validation without sequential delay keep El Salvador on the short list.

    Operator checklist for El Salvador:

    1. Create the SRS-CNEIS-ES account and roles before you promise a board date. Platform access is part of the critical path.
    2. Upload a complete package on the first pass. Parallel review punishes incompleteness twice — both desks ask at once.
    3. Track status inside the platform. Do not invent a parallel email channel that splits the audit trail.
    4. Separate trial authorization from commercial registro thinking. A FIH clearance is not a marketing authorization; keep the investigational file off the commercial hold pattern.
    5. Model hospital fees and site activation as a second workstream. Regulatory parallelism does not auto-complete contracting.

    Related El Salvador posts: FIH step-by-step guide, CNEIS/SRS trial authorization vs registro.

    Parallel review vs pure ethics — choose on purpose

    Parallel review is not “better” than Chile/Costa Rica’s pure-ethics archetype. It is a different product.

    • Buy parallel review when your investors, notified body, or internal QA want a national regulator’s concurrent evaluation on the protocol — and you refuse to pay for that with a sequential backlog.
    • Buy pure ethics when the CEC letter is the authorization you need to open sites, and ministry involvement is import / registry logistics rather than protocol science.

    Confusing the two produces bad decks: Chile sold as “ministry co-approval,” or Panama sold as “ethics only.” Neither story survives diligence.

    Parallel review shortens only one phase. For the whole path from protocol synopsis to first patient, see our phase-by-phase site activation timeline guide.

    What still kills the 30–45 / 30–60 day windows

    Parallelism removes waiting between desks. It does not remove:

    • Incomplete Spanish informed consent or IB
    • Wrong ethics destination (Panama Type I vs Type II)
    • Missing insurance or site letters
    • Import / customs readiness that starts the week you hoped to screen
    • Honest recruitment math in smaller populations

    bioaccess® will tell you the clock on the statute and the clock on your file. They are not the same number until the dossier is complete.

    Submission logistics that make parallelism real

    Parallel review fails in the same place sequential review fails: the first incomplete upload. The difference is you learn it from two desks at once.

    For Panama, treat RESEGIS registration, Type II CBI submission, and MINSA evaluation as one workstream with shared Spanish source files. Assign a single document controller. Version the protocol once. Do not let the ethics PDF and the ministry PDF drift by a forgotten amendment.

    For El Salvador, the SRS-CNEIS-ES platform is the workstream. Role setup, document taxonomy, and in-platform responses are part of Good Clinical Practice hygiene, not IT busywork. If your team answers SRS questions by WhatsApp and CNEIS questions by email, you have rebuilt sequential chaos on top of a parallel system.

    Import readiness belongs on the same Gantt row as review. A 35-day clearance with a device still on a US loading dock is not a 35-day path to first-patient-in. bioaccess® sequences customs, temperature control, and site pharmacy qualification against the expected clearance week — not against hope.

    Audience fit

    This archetype is for sponsors seeking regulatory-authority validation without sequential approval delays — Clinical Operations VPs and Regulatory Affairs leads who must show a ministry or superintendencia touch on the protocol while still protecting a FIH calendar measured in weeks.

    Next: Part 3 — comparative framework and selection matrix across all four countries.

    Talk with bioaccess® when you need a Panama RESEGIS + Type II file or an El Salvador SRS-CNEIS-ES package built for concurrent review — the First-in-Human CRO posture we have held in Latin America since 2010.

  • Pure ethics committee approval in Chile and Costa Rica: zero ministry bottleneck

    If you are a US or EU MedTech or biotech founder staring at the US investigational device exemption (IDE) queue, the first question is usually wrong. The question is not “which Latin American country is fastest.” The question is which archetype of startup you are buying.

    I am Julio Martinez-Clark, CEO of bioaccess®. Chile and Costa Rica sit in the first archetype: pure ethics committee approval. For early-phase medical device and many biopharma programs, an accredited ethics committee (CEC / IRB) is the gate that authorizes clinical operations at research sites. The Ministry of Health does not run a sequential scientific review of the protocol the way a classic agency IND path does.

    This article is Part 1 of a three-part series on Latin America’s rapid-startup archetypes (Chile, Costa Rica, Panama, El Salvador). Part 2 covers parallel review in Panama and El Salvador. Part 3 is the selection matrix. Companion corridor overview: Latin America’s fast-track FIH corridor. General information only — not legal advice. Confirm the filing-day pathway before you lock a calendar.

    The archetype in one sentence

    In Chile and Costa Rica, you get to first-patient-in by clearing an accredited ethics committee — not by waiting for a ministry to finish a separate protocol science queue after ethics is done.

    That does not mean “no paperwork” and it does not mean “no import file.” It means the protocol’s scientific and ethical authorization lives in the CEC / IRB layer. Import and site logistics ride on that clearance instead of sitting behind a second ministry protocol evaluation.

    Chile: Ley 20.120, Decreto 114, and the 45-day CEC clock

    Chile’s human-research frame is Ley 20.120 and its regulation, Decreto 114. Accredited Comités Ético Científicos (CECs) evaluate protocols under a statutory clock: 45 calendar days from a complete submission, with a single founded extension of 20 days available under the regulation. That clock is the planning number sponsors should put on the Gantt chart for ethics — not a marketing estimate.

    For medical devices, the early-phase path is structurally different from a pharmaceutical IND-style review at ANAMED. Device studies sit outside ANAMED’s centralized pharma investigational-product review. The Instituto de Salud Pública (ISP) role that matters for startup is the investigational-device import / provisional research-use authorization that follows CEC clearance. In practice: get the accredited CEC letter first; then work the ISP import file on the back of that clearance. Do not model Chile as “Ministry evaluates the protocol for six months, then ethics starts.”

    Operator implications for Chile:

    • Pick an accredited CEC early and map its meeting calendar. The statute gives you a day count; institutional agendas still decide when your file is complete enough to start the clock.
    • Spanish protocol, informed consent, and investigator’s brochure quality decide whether you burn the 45-day window on questions or clear it once.
    • Treat ISP as the import / research-use authority after CEC — not as a second sequential protocol science gate in the ANAMED drug sense.
    • Site director authorization under the Chilean regulation is a real step. Budget it after CEC (and after ISP when your product path requires it).

    For device-specific ISP investigation vs commercial registro nuance, see our live notes on Chile ISP clinical trial path for medical devices and why ISP treats device and drug trials differently.

    Costa Rica: CONIS-accredited CEC as the authorization to start

    Costa Rica’s Biomedical Research Law (Ley N.° 9234) and its regulations put written approval from a CONIS-accredited Comité Ético Científico at the center of trial initiation. CONIS (Consejo Nacional de Investigación en Salud), under the Ministry of Health, accredits the committees and runs the national protocol registry. That is not the same thing as MINSA running a sequential scientific review of every protocol after ethics.

    For sponsors evaluating FIH / early feasibility outside the US IDE queue, the operational read is:

    • A CONIS-accredited local CEC approves the protocol in writing.
    • The approved project is registered with CONIS before execution activities begin.
    • MINSA does not insert a second, sequential ministry protocol science review of the kind that creates 6–12 month backlogs in sequential markets.

    Phase I and certain ministry-housed CEC paths exist inside the Costa Rican system — confirm filing class on day one. For most early-phase MedTech and biotech founders comparing corridors, the archetype still holds: ethics accreditation is the authorization layer; CONIS registration is the national bookkeeping layer; you are not buying a ministry-after-ethics science queue.

    Operator implications for Costa Rica:

    • Confirm the CEC is CONIS-accredited before you translate a dossier for the wrong committee.
    • Build the Spanish file to ICH-GCP and, for devices, ISO 14155 expectations the committee actually uses.
    • Register with CONIS after CEC approval. Registration is not a substitute for the CEC letter.
    • Model hospital / site institutional authorization separately from the CEC decision.

    See also: Costa Rica FIH activation calendar (CEC, CONIS, canon) and the Costa Rica clinical trials hub.

    What “zero ministry bottleneck” does and does not mean

    Sponsors hear “only ethics” and invent two false stories. Correct both before you brief your board.

    False story 1: There is no government involvement at all.
    Reality: Chile still has ISP import / provisional research-use mechanics after CEC. Costa Rica still has CONIS accreditation and registration under the Ministry of Health structure. “Zero ministry bottleneck” means the ministry is not the sequential protocol-science gate that holds first-patient-in for half a year.

    False story 2: Ethics is a rubber stamp.
    Reality: Accredited CECs in both countries review risk-benefit, consent, insurance, investigator fitness, and protocol science. Incomplete Spanish files restart the clock. Pure-ethics archetypes are fast when the file is complete. They are not shortcuts around subject protection.

    Who this archetype fits

    US/EU MedTech and biotech founders evaluating FIH / early feasibility outside the US IDE queue usually fit Chile or Costa Rica when:

    • You want a clear ethics clock you can put in a financing deck (Chile’s 45-calendar-day CEC frame is the cleanest statutory example).
    • You accept that import / registry steps follow ethics instead of preceding a ministry protocol evaluation.
    • Your program benefits from strong data-rigor perception (Chile) or solid Central American infrastructure with English-friendly operations (Costa Rica), without needing a ministry scientific co-signature on the protocol itself.

    If your board or notified body specifically wants a national regulator’s concurrent protocol evaluation on the docket, look at Part 2 — Panama and El Salvador’s parallel-review archetype — not at stretching Chile or Costa Rica into something they are not.

    Practical startup sequence (both countries)

    1. Freeze the English protocol and IB; commission Spanish translations that a CEC can read without guessing.
    2. Select the accredited CEC (Chile) or CONIS-accredited CEC (Costa Rica) and obtain the current submission checklist and meeting calendar.
    3. Submit a complete ethics package: protocol, IB, informed consent, insurance, investigator CVs, site letters.
    4. Track the statutory or committee clock from the complete-file date, not from the first email.
    5. On favorable CEC decision, open the import / research-use file (Chile ISP) or CONIS registration (Costa Rica) without waiting for a ministry protocol science second pass that this archetype does not require.
    6. Close site contracts, pharmacy / device custody, and screening only after the country-specific start conditions are documented.

    How bioaccess® runs this archetype

    bioaccess® has been the First-in-Human CRO for medical devices in Latin America since 2010. On Chile and Costa Rica files we treat the CEC package as the critical path, keep ISP import or CONIS registration on a parallel logistics track after ethics, and refuse to sell you a sequential ministry fantasy that is not in the statute. When Global Trial Accelerators™ or a country hub on bioaccessla.com already covers a filing detail, we link it rather than invent a new clock.

    Next in this series: Parallel review models in Panama and El Salvador. Then the four-country selection matrix.

    Talk with bioaccess® when you need a Chile or Costa Rica FIH dossier built for the ethics clock you actually have — not the US IDE queue you are trying to step around.

  • Is Latin America or Australia cheaper and faster for an early feasibility study?

    Founders keep asking which early-feasibility destination is cheaper and faster: Latin America or Australia. They want a single winner. There is not one.

    I am Julio Martinez-Clark, CEO of bioaccess®. This is the comparison I reuse when a US MedTech team has already heard the Australia CTN story and the LATAM cost story, and needs a decision frame instead of a brochure. It sits next to the live Australia vs Latin America FIH note and the Early Feasibility Studies pillar.

    One-sentence answer

    Latin America is usually cheaper per patient and can be faster to first patient when the dossier, ethics stack, and import plan are built for the country you chose. Australia stays faster to start when you need an English academic workflow and you are not ready to run a Spanish or Portuguese trámite. Neither wins if the protocol cannot support the FDA conversation you need next.

    Cheaper is not the same as lower total cost

    Per-patient cost in Colombia or Panama is often in a planning band about 40–60% below a comparable US or Australian number for similar procedure work. That band is experience-based from bioaccess® programs since 2010 — not a quote for your protocol.

    Total program cost only wins if you do not pay for a second early feasibility study because the first one was exploratory in a way FDA later ignores. A cheaper study that cannot travel into an IDE conversation under 21 CFR 812.28 is a redo, not a savings.

    Faster depends on which clock you mean

    Australia. CTN/CTX and English ethics make the path look short. The CTN is often not the critical path. Site contracting, device import, and hospital activation still stack. Sponsors who budget “12 weeks to first patient in” from a CTN slide routinely discover the bottleneck was logistics.

    Latin America. There is no single LATAM clock. Colombia (INVIMA), Brazil (ANVISA), Mexico (COFEPRIS), Argentina (ANMAT), and Panama (MINSA / CNBI-accredited ethics) have different ethics and regulator stacks. Panama’s ethics-committee-driven pathway for many early device studies can land in a planning band of about 3–5 months from submission to first patient when the file is complete. Colombia’s CEI clock and INVIMA clock are not the same clock. Pick the country before you translate the packet.

    Four filters that decide the winner

    1. Language and dossier. Australia keeps an English core. LATAM usually does not. INVIMA’s traducción oficial is not a certified PDF from a US vendor. Plan translation from the source language on day one.

    2. Ethics vs regulator. In both regions, ethics can move while another gate is still open. In Australia, HREC approval does not mean the site is open. In Colombia, ethics clearance is not INVIMA authorization. In Panama, Decreto Ejecutivo No. 21 of 2026 (Gaceta Oficial No. 30510-C) sets RESEGIS registration and Type II ethics accreditation as process gates — not as a reason to skip import planning.

    3. Import and device custody. A first-in-human implant or catheter does not travel like a pill. Importer of record, customs, and cold chain decide whether first patient slips after every approval is “done.”

    4. FDA usability. Foreign clinical data can support an IDE conversation when protocol, monitoring, and endpoints were written for that use under 21 CFR 812.28 and ISO 14155. Acceptance is still FDA’s call per submission.

    When Australia is the better early-feasibility pick

    Pick Australia when the device already fits an English academic workflow, the implanting volume you need exists there, and your next FDA interaction is weeks away rather than a full year of LATAM build. It is also the better default if you have no in-country regulatory infrastructure in Latin America and you are not willing to build it for this study.

    When Latin America is the better early-feasibility pick

    Pick Latin America when enrollment speed and procedure volume are the constraint — structural heart, neurovascular, and other high-volume hospital procedures — and you will treat INVIMA, ANVISA, COFEPRIS, or Panama’s CNBI-accredited pathway as a designed pathway instead of a translated Australian packet. It is also the better default when you already need a LATAM authorized representative or in-country holder for a later commercial filing. Trial import and later registro are different trámites; they reward the same discipline.

    The mistake that burns both options

    Copying a US protocol, swapping the letterhead, and calling it an OUS early feasibility study. Australia will make that look viable longer than it is. Latin America will often reject it earlier on a form or a translation, which feels slower and is usually cheaper than discovering after 20 patients that the protocol cannot support the IDE.

    Write the protocol for the data you need FDA to accept. Then pick the country whose ethics, import, and site-activation calendar can deliver that protocol. The region is a tactic. The evidence plan is the strategy.

    Talk with bioaccess® when you need the Australia-vs-LATAM call tied to a concrete early feasibility country plan and an FDA-anchored evidence drawer. Market-access work after the trial is a separate path on our market access page.

  • Does Panama require functional large-animal studies for a medical device FIH?

    Sponsors planning a Panama first-in-human (FIH) medical-device study keep asking the same yes/no question: does MINSA require a functional large-animal study before ethics or Ministry review will move?

    I am Julio Martinez-Clark, CEO of bioaccess®. Short answer: no. Functional large-animal studies are not a hard, across-the-board MINSA requirement for a Panama FIH device study. The longer answer is what you need for the dossier.

    This note sits next to our live Decreto 21 of 2026 explainer and the Panama FIH device guide. It is operator guidance, not legal advice and not a quote.

    One-sentence answer

    Panama’s current clinical-research rulebook sets process and documentation. It does not publish a required animal n, species, or duration for investigational medical devices. On quality standard, Decreto Ejecutivo 21 of 2026, Art. 102, says preclinical studies, when necessary, must follow Good Laboratory Practice (GLP). MINSA’s research office (URIS) confirmed in October 2026 that this applies to preclinical studies performed in Panama. Preclinical studies done abroad do not need to be repeated locally; they must be included in the investigator’s brochure, follow recognized standards, and are assessed by the ethics committee. Formal questions to MINSA go by letter or email to URIS, copying the Dirección General de Salud Pública, not through RESEGIS.

    What the rulebook actually says

    Decreto Ejecutivo No. 21 of 23 April 2026 (Gaceta Oficial No. 30510-C) implements Titles III and IV of Ley 84 of 14 May 2019. For sponsors, the decree turns on three operational gates:

    • Registration on RESEGIS (MINSA’s national research-registration platform) before execution begins
    • Ethics review by a committee accredited by the CNBI (Comité Nacional de Bioética de la Investigación)
    • For higher-risk protocols, MINSA registration plus technical/public-health evaluation via RESEGIS, with ethics review by the accredited committee — which may run in parallel where the committee permits it

    The decree also defines the documentation package — protocol, investigator’s brochure (IB), informed consent, insurance, and related files. The protocol is submitted in Spanish. It does not set a preclinical animal checklist.

    What MINSA and the CNBI-accredited committee actually review

    Reviewers look for a coherent risk-benefit narrative, not a species count. In practice that means:

    • ISO 10993 biocompatibility evidence that is scientifically valid for the contact and duration you claim (GLP under Art. 102 of Decreto Ejecutivo 21 if the studies are performed in Panama; studies done abroad must follow recognized standards and appear in the investigator’s brochure)
    • Mechanical and functional bench data that match the intended use
    • Sterilization and packaging evidence for the investigational configuration
    • An ISO 14971 risk file that ties residual risks to the first-in-human cohort
    • An IB that documents the safety information you actually have

    When the device class, contact duration, or mechanism warrants animal data, that data goes in the narrative. Animal work is a conditional element of the risk story. It is not a statute that says “run a porcine efficacy study or stop.”

    How this differs from a class-specific scientific frame

    Some device classes commonly use large-animal models with functional outcomes, histology, and imaging correlation — for example certain injectable or implant programs where the science community expects that evidence. Treat those models as a scientific frame for that class, not as a Panama statute. Confusing the two is how teams overbuild the wrong study or underbuild the IB.

    What did not get stricter after Decreto 21

    Decreto 21 of 2026 tightened process: ethics accreditation, RESEGIS registration, defined review clocks, and — for high-risk protocols — parallel ethics review where the accredited committee permits it. It did not invent a new large-animal efficacy mandate.

    Operator checklist before you ask for a Panama dictamen

    1. Write one page that states what preclinical evidence you have and what residual risk it leaves for first-in-human use.
    2. Map each residual risk to a control in the protocol (cohort size, stopping rules, imaging, monitoring).
    3. Confirm the IB and ISO 14971 file tell the same story in Spanish for the CNBI-accredited committee.
    4. Register the study in RESEGIS before execution; do not treat ethics approval as a substitute for registration.
    5. If you already have an animal study (or a deliberate gap), ask whether that study closes a risk the IB claims — not whether Panama “requires animals.”

    Talk with bioaccess® when you need the Panama FIH dossier framed for CNBI and MINSA without inventing a statute that is not in Decreto 21.

  • Medical Device Regulatory Consulting: When to Hire a Specialist

    Medical Device Regulatory Consulting: When to Hire a Specialist

    WordPress Category: Navigating Regulatory Landscapes in Latin America

    Medical device regulatory consulting sits at the intersection of science, law, and clinical strategy — and knowing when to bring in a specialist can determine whether your program reaches first-in-human data on schedule or stalls for a year waiting on approvals. For startup founders and CSOs managing a $1M to $5M FIH budget, that distinction is not academic. It is the difference between hitting an investor milestone and missing it.

    This article maps out the decision points where specialist regulatory guidance pays for itself, what to look for in a consultant versus a full-service CRO, and how the regulatory consulting function fits inside a broader FIH execution strategy.

    What Medical Device Regulatory Consulting Actually Covers

    Regulatory consulting for medical devices is not a single service. It spans at least five distinct functional areas, and most sponsors need different combinations depending on their stage.

    Pre-submission strategy. Before you file anything with the FDA, a Pre-Sub (formerly Pre-IDE) meeting can clarify the agency's expectations on study design, endpoints, and the evidence threshold for an IDE or 510(k). A regulatory consultant helps you structure that meeting, draft the questions, and interpret the FDA's written response in a way that shapes your protocol — not just files it away.

    IDE and IND pathway navigation. For investigational devices, the IDE application is the gateway to human studies in the United States. A consultant maps out whether your device requires a significant-risk or non-significant-risk determination, what the IDE application must contain, and how study design decisions made now will affect your eventual 510(k) or PMA submission.

    Protocol and study design alignment. The protocol is not just a clinical document — it is a regulatory artifact. Every endpoint, inclusion criterion, and follow-up interval either supports or complicates your future submission. Regulatory consultants who understand FDA expectations can pressure-test a protocol before it reaches an Ethics Committee (EC) or Institutional Review Board (IRB).

    International regulatory dossier preparation. If your FIH study will run outside the United States — in Colombia, Panama, Chile, or another Latin American market — you need country-specific regulatory dossiers. INVIMA in Colombia, MINSA/CNBI in Panama, and ISP/MINSAL in Chile each have distinct submission requirements. A consultant with in-country experience knows what each authority expects and how to sequence submissions to avoid delays.

    Post-market and registration strategy. Once a device is FDA-cleared or CE-marked, entering Latin American markets requires separate registrations with ANVISA (Brazil), COFEPRIS (Mexico), ANMAT (Argentina), DIGEMID (Peru), and others. This is a distinct regulatory workstream from clinical trial approval, and it requires a different kind of specialist.

    The Four Moments That Signal You Need a Specialist

    Most MedTech startups underestimate how early regulatory consulting should begin. The four clearest triggers are:

    1. You Are Approaching Design Freeze

    Design freeze is the point at which your device's specifications are locked for verification and validation. Changes after that point carry significant regulatory cost. A regulatory consultant engaged before design freeze can confirm that your intended indication, device classification, and predicate strategy are coherent — before the engineering team locks anything in.

    Waiting until after design freeze to engage regulatory counsel is one of the most common and expensive mistakes in early-stage MedTech development.

    2. You Are Preparing a Pre-Sub or IDE Application

    The FDA Pre-Sub process is structured but not simple. A poorly framed Pre-Sub question can produce a response that is technically accurate but operationally unhelpful. A specialist knows how to frame questions so the agency's answers give you actionable guidance on study design, sample size, and endpoint selection.

    For IDE applications, the consultant's role is to ensure the application is complete, that the risk analysis is defensible, and that the clinical protocol meets 21 CFR 812 requirements. An incomplete IDE triggers a deficiency letter — and that can add months to your timeline.

    3. Your FIH Study Will Run in Latin America

    Running a first-in-human study in Latin America requires regulatory expertise that most US-based consultants do not carry. Each country's health authority has its own submission format, language requirements, and review timelines. Ethics Committee approvals and ministry-of-health approvals to conduct the studies are separate processes that must be sequenced correctly.

    In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are observed in 30 to 90 days when submissions are prepared correctly. That speed advantage disappears quickly if the dossier is incomplete or formatted incorrectly for the receiving authority.

    This is where the distinction between a pure regulatory consultant and a full-service CRO becomes important. A consultant can prepare the dossier. A CRO with in-country regulatory infrastructure can prepare the dossier, manage the submission, respond to authority queries, and activate the clinical site — all within the same accountability structure.

    4. You Are Preparing for Market Registration After FDA Clearance

    If your device has received 510(k) clearance or PMA approval and you are targeting Latin American markets, you need a specialist in each country's registration process. ANVISA's registration pathway in Brazil differs substantially from COFEPRIS in Mexico or INVIMA in Colombia. Timelines, required documentation, and in-country holder requirements vary by country and device class.

    Attempting these registrations without country-specific expertise typically results in incomplete submissions, requests for additional information, and delays that push market entry back by 12 to 18 months.

    Regulatory Consultant vs. Full-Service CRO: Where the Line Is

    A regulatory consultant advises. A full-service CRO executes. For early-stage sponsors, the practical question is which one your program actually needs at a given point.

    A standalone regulatory consultant is appropriate when your primary need is strategic guidance: Pre-Sub preparation, IDE pathway analysis, classification review, or a gap assessment of your technical file. The output is a document or a recommendation. Execution stays with your internal team.

    A full-service CRO with regulatory capabilities is appropriate when execution is the bottleneck. If you need regulatory dossiers filed in three countries, Ethics Committee submissions managed, sites activated, patients enrolled, and data collected to ISO 14155 and FDA 21 CFR 812.28 standards — all within a 12-month window — a consultant relationship is structurally insufficient. You need a team that owns the process end to end.

    The risk of using a consultant when you need a CRO is diffuse accountability. The consultant delivers a strategy document. Who files the INVIMA submission? Who manages the EC query response? Who ensures the data management system produces an FDA-submissible dataset? When those questions have no clear owner, timelines slip.

    What FDA Data Bridging Requires from Your Regulatory Setup

    A common concern among US-based sponsors considering OUS early clinical studies is whether data collected outside the United States will hold up with the FDA. The answer depends entirely on how the study is structured and documented.

    Data collected under ISO 14155 and structured per FDA 21 CFR 812.28 is accepted for US IDE and IND submissions. That is not a LatAm-specific rule — it is the standard the FDA applies to any international clinical data submitted in support of a US application. The regulatory consultant or CRO you engage must have explicit experience building evidence packages to this standard, not just running compliant trials in their home jurisdiction.

    This is a non-negotiable qualification when evaluating regulatory partners for an OUS FIH study. Ask specifically: has the team prepared an FDA-submissible evidence package from a LatAm study? What was the submission type, and what was the FDA's response?

    How bioaccess® Integrates Regulatory Consulting Into FIH Execution

    bioaccess® operates as a Miami-headquartered CRO with a site network spanning more than 50 pre-qualified sites across 19 Latin American and Caribbean markets. The FIH-12™ program structures regulatory execution as one of nine workstreams inside a 12-month engagement — covering FDA Pre-Sub and IDE/IND pathway alignment, country-specific dossier preparation, Ethics Committee submissions, and ministry-of-health approvals to conduct the studies.

    The regulatory workstream does not operate in isolation. Protocol development, site activation, patient enrollment, data management, and submission-ready evidence package delivery are managed by the same team. That single-team accountability model addresses the diffuse accountability problem that arises when regulatory consulting and clinical execution are split across separate vendors.

    For sponsors who have already achieved FDA clearance or CE marking, bioaccess® market access provides in-country holder and Importer of Record registration across ANVISA, INVIMA, COFEPRIS, ANMAT, ISP (Chile), DIGEMID (Peru), and other regional authorities — a distinct regulatory workstream managed through the same operational infrastructure.

    The Cook Group program illustrates what integrated regulatory execution looks like at scale. In the multi-site first-in-human artificial venous valve study in Colombia, bioaccess® managed more than 142 INVIMA regulatory submissions across a complex multi-site engagement. That volume of regulatory activity requires more than advisory capacity — it requires in-country infrastructure and dedicated regulatory operations staff.

    ClarVista Medical's program demonstrates how regulatory execution inside a structured FIH engagement can support a commercial outcome. The ClarVista first-in-human program in Latin America produced the clinical evidence that supported the company's eventual acquisition by Alcon. The regulatory pathway was built to produce FDA-bridgeable data from the outset.

    For sponsors at the market-registration stage, the CryoConcepts COFEPRIS registration program in Mexico shows how a structured in-country regulatory engagement handles the Histafreezer STAT device registration and regulatory transition — a process that requires country-specific expertise that general regulatory consultants rarely carry.

    Questions to Ask Before Engaging Any Regulatory Specialist

    Before signing an engagement with a regulatory consultant or CRO, these questions will surface gaps in capability or fit:

    • Have you prepared regulatory dossiers for submission to INVIMA, MINSA/CNBI, ISP/MINSAL, or other LatAm authorities? For what device types?
    • Can you produce an evidence package structured to FDA 21 CFR 812.28 from an OUS study? What submissions have you supported with that package?
    • Who owns the regulatory submission process end to end — the consultant, a subcontractor, or in-country staff?
    • What is your observed timeline for ethics and ministry-of-health approvals in the countries you operate in?
    • How do you handle authority queries during the review period? What is your average response time?
    • Do you have experience with the specific device classification or indication relevant to our program?

    The answers will tell you whether you are engaging an advisor or an operator — and whether that distinction matters for your current stage.

    Regulatory Consulting Across the Device Development Lifecycle

    Regulatory consulting needs shift as a device program matures. A rough map:

    Pre-clinical to IDE-ready: Classification review, Pre-Sub strategy, IDE application preparation, protocol pressure-testing against FDA expectations.

    IDE-approved to FIH: Country selection for OUS studies, regulatory dossier preparation, Ethics Committee submissions, ministry-of-health approvals, site qualification.

    FIH data to US submission: Evidence package structuring to 21 CFR 812.28 and ISO 14155, FDA Pre-Sub follow-up, IDE supplement or 510(k)/PMA preparation.

    Post-clearance to LatAm market entry: ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID registrations, in-country holder designation, Importer of Record setup.

    Each phase requires a different depth of regulatory expertise. A consultant who is strong on Pre-Sub strategy may have no infrastructure for INVIMA submissions. A CRO strong in FIH execution may not carry the post-market registration capability you need 18 months later.

    The Envveno Medical program illustrates this lifecycle in practice. The LATAM FIH execution built the clinical foundation that supported the first-ever FDA IDE for a non-surgical replacement venous valve. Regulatory strategy and clinical execution were not separate workstreams — they were built together from the start.

    Frequently Asked Questions

    What does a medical device regulatory consultant do?
    A medical device regulatory consultant advises sponsors on FDA classification, Pre-Sub strategy, IDE and 510(k) pathway selection, and international regulatory dossier requirements. The scope is advisory; execution typically remains with the sponsor's internal team or a CRO.

    When should a MedTech startup hire a regulatory consultant?
    The clearest triggers are approaching design freeze, preparing a Pre-Sub or IDE application, planning an OUS first-in-human study, or preparing for market registration in Latin American countries after FDA clearance. Engaging before design freeze is almost always more cost-effective than engaging after.

    What is the difference between a regulatory consultant and a CRO?
    A regulatory consultant provides strategic guidance and prepares documents. A CRO executes the clinical and regulatory program — filing submissions, managing Ethics Committee and ministry-of-health approvals, activating sites, enrolling patients, and delivering a submission-ready evidence package. When execution is the bottleneck, a CRO with integrated regulatory capability is the appropriate choice.

    Will data from a Latin American FIH study be accepted by the FDA?
    Data collected under ISO 14155 and structured per FDA 21 CFR 812.28 is accepted for US IDE and IND submissions. The study must be designed and documented to those standards from the outset — this is not automatic. It requires a regulatory partner with explicit experience building FDA-submissible evidence packages from OUS studies.

    How long do regulatory approvals take in Latin American countries?
    In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are observed in 30 to 90 days when submissions are prepared correctly. These are observed ranges, not guarantees, and they depend on complete, correctly formatted dossiers submitted to the right authorities in the right sequence.

    What regulatory bodies govern medical device trials in Latin America?
    Key authorities include INVIMA (Colombia), MINSA/CNBI (Panama), ISP/MINSAL (Chile), SRS/CNEIS (El Salvador), ANVISA (Brazil), COFEPRIS (Mexico), ANMAT (Argentina), and DIGEMID (Peru). Each has distinct submission requirements, review timelines, and in-country holder rules.

    Can a single partner handle both FIH regulatory execution and post-market registration in Latin America?
    Yes, if the partner has both clinical trial infrastructure and post-market registration capability across the relevant countries. bioaccess® covers both through the FIH-12™ program for clinical execution and bioaccess® market access for in-country holder and Importer of Record registration across ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID, and other regional authorities.

    The Right Specialist at the Right Stage

    Medical device regulatory consulting is not a single engagement type. It is a set of capabilities that your program needs at different intensities across the development lifecycle. The question is not whether to hire a specialist — it is which kind, at which stage, and with what accountability structure.

    For programs at the FIH stage targeting Latin American execution, the regulatory workstream cannot be separated from clinical operations without creating accountability gaps that cost time and capital. The sponsor's financial runway rarely accommodates those gaps.

    To understand how bioaccess® structures regulatory execution inside a 12-month FIH program, visit bioaccessla.com.

  • First-in-Human Medical Device Trials in China

    China is the only one of the ten busiest countries in our data where early device study registrations rose sharply, but the work is mostly domestic. This guide covers how a first-in-human (FIH) or early feasibility study (EFS) is regulated there, what the registry shows, and what that means for a United States (US) sponsor weighing China against Latin America.

    What the registry shows

    Our query of ClinicalTrials.gov (CT.gov) found 108 early-stage, industry-sponsored device studies with at least one site in China, first posted between 1 January 2021 and 28 September 2026. That ranks China #7 worldwide on this measure. Of these, 49 used FIH, feasibility or pilot language in the title or summary, and 22 explicitly described a first-in-human or early feasibility study. 17 were run by sponsors headquartered outside China, 11 of them by US-headquartered companies, and 3 also listed sites in another country. Registrations went from 47 in 2021–2023 to 61 from January 2024 to September 2026. Sponsor headquarters could not be resolved for 11 studies, so the home-country count is a floor.

    Method: bioaccess® analysis of the ClinicalTrials.gov (CT.gov) application programming interface (API) v2, run 28 September 2026: industry-sponsored interventional device studies first posted 1 January 2021 to 28 September 2026 (6,045). Early-stage means FIH, early feasibility, feasibility or pilot wording, or phase N/A with 50 or fewer planned participants (2,968 worldwide). Sponsor headquarters were inferred for 95% of studies. Counts are registrations, not approvals, and recent years are under-counted.

    How device trials are regulated in China

    Device trials in China follow the Provisions for Medical Device Registration and Filing (State Administration for Market Regulation (SAMR) Decree No. 47, effective 1 October 2021), administered by the National Medical Products Administration (NMPA).

    • Filed sites and good clinical practice: trials must follow device good clinical practice (GCP) at qualified institutions that have filed with the authorities, and each trial is filed with the provincial regulator (Art. 37).
    • High-risk class III devices: devices on NMPA’s catalogue need NMPA approval before the trial and must be studied in top-tier (tertiary grade A) hospitals (Art. 38). NMPA decides within 60 days of accepting the application, and the result is published through its Center for Medical Device Evaluation (CMDE). If NMPA does not respond in time, the trial counts as approved (Art. 40).
    • Overseas companies need a legal agent in China (Art. 14).
    • Human genetic resources (HGR): under China’s 2019 HGR regulations, foreign entities may not collect or store Chinese human genetic resources themselves or send them abroad. Work involving such material needs Chinese partners, the relevant approvals or filings, and ethics review. Plan for this if your study collects biological samples.

    Where China is strong

    • Growth: the only sharp rise in registrations among the ten countries with the most studies (about +42% annualized).
    • FIH volume: 22 of 108 studies were explicitly FIH or EFS, more than any European country we profiled.
    • Cardiovascular scale: Cardiovascular (63 studies), oncology (15) and neurology (10) led the mix, and cardiovascular alone made up more than half.

    Using data from China in a US submission

    The US Food and Drug Administration (FDA) can accept device data from outside the United States under the Code of Federal Regulations (CFR) at 21 CFR 812.28 if the study follows good clinical practice (GCP), including independent ethics review and informed consent, the sponsor supplies the required supporting information, and FDA can validate the data, if needed by inspection. The rule covers studies begun on or after 21 February 2019. FDA recognizes the International Organization for Standardization (ISO) device GCP standard, ISO 14155:2020; check the recognition status of the 2026 edition before you plan to it. Meeting 812.28 is not clearance or approval, and FDA may still ask for US data. Confirm your plan through a pre-submission under FDA’s Q-Submission (Q-Sub) program.

    How Latin America compares

    China’s early device work is overwhelmingly domestic (80 of 108 studies had Chinese-headquartered sponsors), and China is 12 hours ahead of US Eastern during US daylight saving time and 13 otherwise. Across the 15 Latin American countries we track, the same query found 132 early-stage device studies in total. 38 of them were explicitly FIH or EFS, which is 12% of the 310 such studies worldwide, and 102 (77%) had US-headquartered sponsors. The region is used mainly for US companies’ first human data.

    • Time zone: Panama stays on UTC−5 (Coordinated Universal Time minus five) all year, the same as US Eastern Standard Time.
    • Regulation: each Latin American country has its own national pathway. We don’t quote a single clock; country planning ranges come with each proposal.
    • Ethics: bioaccess® treats as study-specific, timed to each committee’s meeting schedule, the planning for ethics review in its lead countries. This is based on our experience, not a formal study, and it is not a guarantee.
    • Cost: we don’t publish per-patient figures. Compare line-item budgets, including monitoring travel and translation.
    • Where we work: bioaccess® has focused on FIH studies since 2010. We lead execution in Panama, El Salvador, Chile and the Dominican Republic, with 50+ pre-qualified sites across 19 countries.

    When China is the better fit: if the Chinese market is your first commercial target, you have a Chinese partner and legal agent, and your data plan fits the HGR rules. For a US company whose first goal is FDA, Latin America offers a US-aligned time zone and a long record with US sponsors.

    Frequently asked questions

    Does a first-in-human device trial in China need NMPA approval?

    High-risk class III devices on NMPA’s catalogue need NMPA approval, decided within 60 days of acceptance, and must be studied in tertiary grade A hospitals. Other trials are filed with the provincial regulator and run at filed, qualified institutions under GCP.

    Can a foreign company run a device trial in China directly?

    Overseas companies need a legal agent in China. Under the 2019 human genetic resources regulations, foreign entities also may not collect or store Chinese human genetic resources themselves or send them abroad.

    Can data from a Chinese first-in-human study support an FDA submission?

    It can, if the study meets 21 CFR 812.28 and FDA can validate the data, including by inspection. Sample-export limits under China’s HGR rules may affect what can be verified outside China. Acceptance is not clearance or approval.

    How does China compare with Latin America for a US sponsor’s first-in-human study?

    China has volume and growth, mostly for domestic sponsors, 12–13 hours from US Eastern. Latin American sites work mainly with US sponsors, and Panama keeps US Eastern Standard Time all year.

    Next step

    Weighing China against Latin America for an FIH or EFS study? Book a call with Julio Martinez-Clark to review your device class, endpoints and FDA plan.

    Sources

  • Vantage Clinical in Kazakhstan, and Where Latin America Fits

    General information, not legal or regulatory advice. bioaccess® does not speak for Vantage. Statements about Vantage are attributed to its public website (vantage-ct.com) and its newsletter, The Vantage Brief, as of 28 September 2026. Confirm any detail that matters to your program with Vantage directly.

    If you searched Vantage Clinical, Vantage Kazakhstan, or vantage-ct, you are probably weighing Kazakhstan for an early-phase clinical trial. This page does three things. It separates the Kazakhstan platform from a U.S. site network with a similar name. It summarizes what Vantage publicly says it offers. And it explains where Latin America, and bioaccess®, The First-in-Human CRO (contract research organization), fit when your program includes a medical device first-in-human (FIH) study.

    First, which “Vantage”?

    Two unrelated organizations show up for this search:

    • Vantage Clinical (vantage-ct.com). Describes itself as sovereign-backed clinical trial infrastructure in Kazakhstan, built by biotech operators and investors. It lists locations in New York, Dubai, and Astana, and its site footer uses the name “Vantage Clinical Trials.” The Vantage Brief lists Charlie Regis, Almas Kenessary, and Zach Lomis as co-founders and partners, and Didar Bitmanov as chief operating officer (COO).
    • Vantage Clinical Trials (vantagetrials.com). An independent clinical research site network in the Tampa Bay area of Florida, founded in 2018, with sites in Tampa, St. Petersburg, and The Villages.

    This page is about the first one.

    What Vantage says it offers in Kazakhstan

    Vantage calls itself “the Kazakhstan layer”: the in-country platform, while sponsors keep flexibility on which CRO they use. Its website lists four parts:

    • Government integration. Direct ministerial relationships and sovereign backing.
    • Site and principal investigator (PI) network. Government-owned hospitals, Joint Commission International (JCI)-accredited facilities, and in-country site contracting, qualification, and activation.
    • Accelerated recruitment. A centralized digital health database that Vantage says covers 20 million citizens.
    • Regulatory navigation. Local approvals coordinated with Kazakhstan’s National Center for Drugs and Medical Devices Evaluation, with protocols built around International Council for Harmonisation (ICH) E6(R2) Good Clinical Practice (GCP).

    Vantage describes itself as CRO-agnostic. Sponsors can bring their existing CRO, or Vantage coordinates with global CROs. Its newsletter names Tigermed as its global CRO partner. Its feasibility form covers first-in-human and proof-of-concept (POC) studies through Phase 3. Its June 2026 newsletter describes a first-in-human feasibility study of a bioresorbable peripheral vascular scaffold at a national hospital in Astana.

    Vantage also publishes performance figures for Kazakhstan, such as 2–3x faster enrollment, 20–30% of Western cost, and 250+ completed and ongoing trials in the country. Those are Vantage’s figures. bioaccess® has not independently checked them, and we do not repeat them as our own. If a number matters to your budget, ask Vantage what it is based on.

    Where Latin America fits

    Kazakhstan and Latin America are not an either/or choice. They can answer different questions in an early-stage plan. bioaccess® has focused on first-in-human and early feasibility studies (EFS) since 2010. Most of our sponsors are U.S. medical device startups. We anchor on U.S. regulatory strategy and run studies across a defined list of 19 Latin American and Caribbean countries.

    Three situations where Latin America is worth a look alongside a Kazakhstan plan:

    1. Device-first programs. If your first human milestone is a device FIH or EFS, Latin America offers pre-qualified sites with small-cohort device experience, in time zones close to the U.S. Later-phase or larger cohorts can go wherever your regulatory strategy points, Kazakhstan included.
    2. A second geography. Early-phase plans often stall for reasons unrelated to the science: a site’s calendar, an import permit, a regulator’s queue. A second country in a different region lowers single-country risk.
    3. Hands-on oversight from the U.S. Some sponsor teams want to be in the room for the first cases. Short flights and overlapping working hours make that practical in Latin America.

    Neither region is automatically faster or cheaper for every protocol. Match the geography to the device, the U.S. Food and Drug Administration (FDA) pathway, and what your investors need to see.

    At a glance

    Kazakhstan via Vantage Latin America via bioaccess®
    What it is In-country platform: government integration, sites, recruitment, regulatory navigation (per vantage-ct.com) First-in-human CRO: U.S. regulatory anchoring plus Latin American execution (per bioaccessla.com)
    CRO model CRO-agnostic; names Tigermed as global CRO partner bioaccess® is the CRO
    Stages listed publicly FIH and POC through Phase 3 FIH and EFS
    Geography Kazakhstan; offices listed in New York, Dubai, Astana 19 Latin American and Caribbean countries; headquartered in Miami
    Sites Government-owned hospitals and JCI-accredited facilities 50+ pre-qualified sites
    FDA rule for foreign data Vantage cites 21 CFR 312.120 (U.S. Code of Federal Regulations; drugs and biologics) 21 CFR 812.28 (devices); eligibility is not clearance
    First contact info@vantage-ct.com Schedule time with Julio Martinez-Clark

    FDA and foreign data, briefly

    FDA does not keep a country scorecard. For drugs and biologics, FDA considers foreign clinical data under 21 CFR 312.120. For devices, 21 CFR 812.28 lets FDA accept data from studies outside the U.S. to support an investigational device exemption (IDE) or a marketing submission, when the study followed GCP (for devices, usually ISO 14155, the International Organization for Standardization standard for device trials), had independent ethics review and informed consent, and FDA can validate the data, including by inspection if needed. Eligibility is not clearance or approval. Plan the bridge with FDA early, usually through a Pre-Submission meeting. More detail: Does the FDA accept clinical data from Latin America? and Can first-in-human data from outside the U.S. support an FDA IDE submission?

    Related pages

    Frequently asked questions

    Is Vantage Clinical the same company as Vantage Clinical Trials in Florida?

    No. Vantage Clinical (vantage-ct.com) is a clinical trial platform focused on Kazakhstan, with offices listed in New York, Dubai, and Astana. Vantage Clinical Trials (vantagetrials.com) is an independent research site network in the Tampa Bay area of Florida, founded in 2018. They are separate organizations.

    Is bioaccess® part of Vantage?

    No. bioaccess® and Vantage are independent companies. bioaccess® is The First-in-Human CRO, headquartered in Miami and focused on the U.S. and Latin America. If your plan includes both Kazakhstan and Latin America, tell us and we will coordinate with your Kazakhstan partner.

    Does Vantage run medical device trials?

    Vantage’s feasibility form lists first-in-human and proof-of-concept studies through Phase 3, and its June 2026 newsletter describes a first-in-human feasibility study of a bioresorbable peripheral vascular scaffold at a national hospital in Astana. For specifics on devices in Kazakhstan, ask Vantage directly.

    Will the FDA accept data from Kazakhstan or Latin America?

    FDA decides case by case, not by country. It considers foreign drug and biologic data under 21 CFR 312.120 and foreign device data under 21 CFR 812.28, looking at GCP compliance, ethics review, informed consent, and whether it can validate the data. Eligibility is not clearance or approval, so align the plan with FDA early, usually through a Pre-Submission meeting.

    Can one program use both Kazakhstan and Latin America?

    Yes. Sequencing the two regions is usually simpler than running both under one protocol at the same time, because each has its own regulator, ethics committees, language, and import logistics. One sequence to consider: a device first-in-human or early feasibility study in Latin America, then larger or later-phase cohorts wherever your regulatory strategy points.

    How do I start a conversation?

    For Kazakhstan feasibility, contact Vantage at info@vantage-ct.com. For a device first-in-human or early feasibility study in Latin America, schedule time with Julio Martinez-Clark, CEO of bioaccess®, at bioaccessla.com/schedule-time-with-julio-martinez-clark.

    Next step

    Planning a device first-in-human study and weighing Kazakhstan, Latin America, or both? Schedule time with Julio Martinez-Clark, CEO of bioaccess®.

    Schedule time with Julio Martinez-Clark

  • Kazakhstan Medical Device Trial Approval: Who Signs Off, What the Rules Say, and How Latin America Compares

    General information, not legal or regulatory advice. Sources were checked on 28 September 2026. bioaccess® does not run studies in Kazakhstan and is not affiliated with any company named here.

    If you searched for “Kazakhstan device trial approval”, you probably want to know who approves an interventional medical device study there, what standards apply, and whether it makes sense for a first-in-human (FIH) or early feasibility study (EFS). This page summarizes the framework from public legal sources and then compares it fairly with a Latin American start.

    Who approves an interventional device trial

    A legal overview published on Legal 500 describes three steps:

    1. Expert review. The National Center for Expertise of Medicines and Medical Devices examines the clinical trial materials and issues a conclusion.
    2. Bioethics review. The Central Commission on Bioethics reviews interventional trials of foreign-produced medicines and devices, as well as trials at two or more centers in Kazakhstan. Local bioethics commissions handle single-center studies, except interventional trials of products made outside Kazakhstan. For a foreign device FIH, plan on the Central Commission.
    3. Permission. The Committee for Medical and Pharmaceutical Control of the Ministry of Healthcare issues the permit and conducts clinical-trial inspections.

    The legal framework

    The same overview lists the main instruments:

    • The Code on Public Health and the Healthcare System (No. 360-VI, 7 July 2020).
    • The Eurasian Economic Union (EAEU) Rules of Good Clinical Practice (Decision No. 79, 3 November 2016) and Kazakhstan’s own good clinical practice (GCP) standard (Order ҚР ДСМ-15, 4 February 2021).
    • ISO 14155 through Eurasian Economic Commission Recommendation No. 17 (4 September 2017) on device trials involving human subjects.
    • The rules for conducting clinical trials and the requirements for clinical sites (Order ҚР ДСМ-248/2020, 11 December 2020).

    Other points from the overview that matter for planning:

    • Site requirements: a medical license, standard operating procedures (SOPs) for trials, suitable equipment or contracted services, GCP-trained staff, and intensive care capability where the protocol requires it.
    • Participant restrictions: interventional trials may not enroll military or law-enforcement personnel, employees of the medical organization where the research takes place, or people in penal institutions.
    • Records: the sponsor and investigator must archive trial documents for 25 years after completion.
    • The overview notes that draft amendments were under public discussion when it was published, so confirm the current text.

    What is published about timelines

    We did not find an official, device-specific end-to-end timeline in the sources above. Ask for a written calendar that covers the expert review, the Central Commission on Bioethics and the Ministry permit.

    Standards and U.S. data acceptance

    The U.S. Food and Drug Administration (FDA) accepts device data from outside the United States under 21 CFR 812.28 when the study is well designed and well conducted under GCP, with independent ethics review and informed consent, and FDA can validate the data. That data can support an investigational device exemption (IDE), 510(k), De Novo or premarket approval (PMA) submission. Kazakhstan’s reference to ISO 14155 fits that expectation. What matters is how the study is actually run.

    Patients, sites and device experience

    • Population: about 20.6 million (World Bank, 2024).
    • ClinicalTrials.gov (28 September 2026): 26 interventional device records list a site in Kazakhstan. None has “device feasibility” as its primary purpose, which suggests early-device experience is still limited.
    • Kazakhstan does not appear on Clinical Accelerator’s public coverage map.

    Recruitment reality: with a thin FIH track record, you will depend more heavily on individual investigators’ experience with your device type. Strict inclusion criteria can shrink eligible pools quickly. Verify screening numbers for your criteria at each named site.

    Logistics from the United States

    • Time zone: Astana is on UTC+5 (Coordinated Universal Time plus five hours), 9–10 hours ahead of U.S. Eastern time.
    • Languages: Kazakh and Russian. Confirm the translation requirements for the protocol and informed consent form (ICF).
    • Check the U.S. Department of State travel advisory and current routings.

    Genuine strengths

    Kazakhstan has a codified framework that explicitly references ISO 14155 and EAEU GCP, a defined inspection authority, clear site requirements, and a mid-sized population. For sponsors who also have Eurasian market plans, running work there can be strategically useful.

    How Latin America compares

    • Same FDA rule: 21 CFR 812.28.
    • Early-device track record: on ClinicalTrials.gov, Panama has 5 records with “device feasibility” as their primary purpose, Chile 4 and Brazil 15.
    • Published clocks: our Panama hub publishes 3–5 week ethics approval and a 6–8 week average to first patient with bioaccess® coordination. Argentina’s ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) regulates device clinical investigations under Disposition 969/1997. See our Argentina hub.
    • Time zone: 0–2 hours from U.S. Eastern.
    • U.S. continuity: bioaccess® is headquartered in Miami, and its sister organization Amavita Research Services runs a Miami device and early feasibility study site.
    • Trade-offs: Spanish or Portuguese documents and investigational import permits.

    Other country guides: Uzbekistan

    Frequently asked questions

    Who issues permission for a device trial in Kazakhstan?

    The Committee for Medical and Pharmaceutical Control of the Ministry of Healthcare issues the permit. It relies on a conclusion from the National Center for Expertise of Medicines and Medical Devices and a bioethics opinion.

    Which ethics body reviews a foreign device trial?

    For interventional trials of foreign-produced devices, the Central Commission on Bioethics reviews the study, according to the published legal overview.

    Does Kazakhstan follow ISO 14155?

    Yes. A Eurasian Economic Commission recommendation on device good clinical practice, based on ISO 14155, is part of the framework.

    Will the FDA accept data from Kazakhstan?

    It can. Under 21 CFR 812.28, FDA accepts data from outside the United States from studies run under GCP that it can validate. The decision is made case by case.

    How long does approval take?

    We found no official device-specific figure. Ask for a written calendar.

    Next step

    Comparing Kazakhstan with a Latin American start? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.